Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) EBT Margin (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBT Margin for 2 consecutive years, with 43.4% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 15956.0% to 43.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 69.08%, a 8155.0% increase, with the full-year FY2025 number at 69.1%, down 173.0% from a year prior.
  • EBT Margin was 43.4% for Q4 2025 at Day One Biopharmaceuticals, up from 49.48% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 37.28% in Q3 2024 to a low of 1353.09% in Q2 2024.